Develops treatments for patients with high unmet medical needs, focusing on gastrointestinal and rare diseases.
Processa Pharmaceuticals, Inc., headquartered in Hanover, Maryland, is a dynamic clinical-stage biopharmaceutical company dedicated to addressing critical medical needs across the United States. Established in 2011, Processa Pharmaceuticals focuses on advancing innovative drug products to serve patients with conditions that lack effective treatment options. At the forefront of its development pipeline is PCS499, an oral tablet currently undergoing Phase 2B clinical trials for ulcerative and non-ulcerative necrobiosis lipoidica, a chronic and visually disfiguring skin condition.
Beyond PCS499, Processa Pharmaceuticals is actively progressing several promising candidates. PCS12852, a selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist, is in Phase 2A clinical trials for indications including gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia. The company also focuses on PCS3117, a cytosine analog under Phase 2B trials for pancreatic and non-small cell lung cancers, and PCS6422, an oral inhibitor of dihydropyrimidine dehydrogenase in Phase 1B trials for metastatic colorectal and breast cancers. Additionally, Processa Pharmaceuticals is developing PCS11T, an analog of SN38 and irinotecan, aimed at treating various types of cancer.
Driven by a commitment to innovation and patient-centric care, Processa Pharmaceuticals leverages its robust research and development capabilities to advance novel therapies that address significant medical challenges. Through strategic clinical trials and partnerships, the company strives to improve treatment outcomes and enhance quality of life for patients battling complex and underserved conditions, solidifying its role in shaping the future of biopharmaceutical innovation.